Eurofarma is an international pharmaceutical company with 100% Brazilian capital, operating in 22 countries, including all of Latin America, the US, and parts of the African continent. It is also identified as one of the seven national biologicals companies in the Brazilian Health Surveillance Agency's (Agência Nacional de Vigilância Sanitária, ANVISA) database [1]. Eurofarma has one filgrastim follow-on biological, Fiprima, approved by ANVISA in 2015 [2]. 

In 2012, the Sanofi group signed an agreement to acquire the Colombian generic drug manufacturer Genfar, which made it the market leader in Colombia, expanding its portfolio of affordable pharmaceutical products in Latin America [3]. 

Genfar will become the generic brand of Eurofarma for all Latin American countries, excluding the Brazilian market. Already in December 2010, Eurofarma acquired Segmenta [4].

Genfar includes a portfolio of 144 molecules in 12 different therapeutic classes across 350 products. With the closing of this deal, Eurofarma incorporates more than 500 employees, the entire product portfolio and pipeline of Genfar, in addition to a production factory and the company's Development and Innovation Center in Cali, Colombia.

With the acquisition of Genfar, Eurofarma solidifies its position as the second-largest player in sale of drugs to the retail market in the Latin American region. Eurofarma's international CEO, Marco Billi, stated, ‘The acquisition consolidates our presence in the region and helps us with international advancement, where we continue to grow and reinvest in the business through our commercial strength, innovation, and merger and acquisition activities.’

Since the introduction of generic drugs in Brazil in 2001, the country’s pharmaceutical industry has undergone a transformation. This has increased general availability of many medicines, despite Big Pharma’s threats to reduce their investments in Brazil’s pharmaceutical sector [4].

Related articles
Generic drug growth in Brazil and Venezuela

Brazil to remove backlog for generics

References
1. GaBI Online - Generics and Biosimilars Initiative. Prospects for producing follow-on biological products in Brazil [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Dec 12]. Available from: www.gabionline.net/biosimilars/research/Prospects-for-producing-follow-on-biological-products-in-Brazil
2. GaBI Online - Generics and Biosimilars Initiative. Filgrastim follow-on biological approved in Brazil [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Dec 12]. Available from: www.gabionline.net/biosimilars/news/Filgrastim-follow-on-biological-approved-in-Brazil
3. GaBI Online - Generics and Biosimilars Initiative. Sanofi to acquire Colombian generics maker [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Dec 12]. Available from: www.gabionline.net/pharma-news/Sanofi-to-acquire-Colombian-generics-maker
4. GaBI Online - Generics and Biosimilars Initiative. The pharmaceutical market in Brazil [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Dec 12]. Available from: www.gabionline.net/generics/general/The-pharmaceutical-market-in-Brazil

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2023 Pro Pharma Communications International. All Rights Reserved.